APTOF · As filed with the SEC
Aptose Biosciences balance sheet, by quarter
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||
| Cash and cash equivalents | — | 935,000 | 613,000 | 553,000 | 4,743,000 | 6,152,000 | 7,962,000 | 8,330,000 |
| Restricted cash equivalents, current | — | — | — | 745,000 | — | 555,000 | — | — |
| Restricted cash and restricted cash equivalents | — | 3,161,000 | 1,024,000 | — | — | — | — | — |
| Cash | 1,020,000 | — | — | — | — | — | — | — |
| Restricted cash | 3,085,000 | — | — | — | — | — | — | — |
| Prepaid expenses | 1,845,000 | 2,209,000 | 2,013,000 | 1,857,000 | 1,952,000 | 2,253,000 | 912,000 | 1,236,000 |
| Other current assets | 205,000 | 141,000 | 127,000 | 116,000 | 274,000 | 570,000 | 1,361,000 | 593,000 |
| Total current assets | 6,155,000 | 6,446,000 | 3,777,000 | 3,271,000 | 6,969,000 | 9,530,000 | 10,235,000 | 10,159,000 |
| Non-current assets: | ||||||||
| Property and equipment, net | 2,000 | 4,000 | 8,000 | 19,000 | 23,000 | 26,000 | 30,000 | 34,000 |
| Right-of-use assets, operating leases | 71,000 | 175,000 | 277,000 | 377,000 | 475,000 | 571,000 | 664,000 | 756,000 |
| Other long-term assets | 4,495,000 | 3,387,000 | 2,279,000 | 1,924,000 | — | — | — | — |
| Total non-current assets | 4,568,000 | 3,566,000 | 2,564,000 | 2,320,000 | 498,000 | 597,000 | 694,000 | 790,000 |
| Total assets | 10,723,000 | 10,012,000 | 6,341,000 | 5,591,000 | 7,467,000 | 10,127,000 | 10,929,000 | 10,949,000 |
| Current liabilities: | ||||||||
| Accounts payable to related parties | — | — | — | — | — | 0 | — | — |
| Accounts payable | 3,810,000 | 2,911,000 | 1,456,000 | 2,879,000 | 2,390,000 | 1,258,000 | 1,830,000 | 7,111,000 |
| Accrued liabilities | 7,349,000 | 6,202,000 | 4,804,000 | 5,414,000 | 3,324,000 | 2,773,000 | 7,512,000 | 5,196,000 |
| Current portion of lease liability, operating leases | 80,000 | 193,000 | 305,000 | 413,000 | 441,000 | 428,000 | 416,000 | 404,000 |
| Interest on related party loan payable | — | — | 514,000 | 294,000 | 163,000 | — | — | — |
| Total current liabilities | 11,239,000 | 9,306,000 | 7,079,000 | 9,000,000 | 6,318,000 | 4,459,000 | 9,758,000 | 12,711,000 |
| Non-current liabilities: | ||||||||
| Lease liability, operating leases | — | 0 | 0 | 0 | 80,000 | 193,000 | 305,000 | 414,000 |
| Loan payable to related party | — | — | — | — | — | 10,018,000 | 10,000,000 | — |
| Loan payable to related party | 32,870,000 | 27,018,000 | 18,712,000 | 10,962,000 | 8,462,000 | — | — | — |
| Interest on related party loan payable | 1,286,000 | 855,000 | — | — | — | — | — | — |
| Total non-current liabilities | 34,156,000 | 27,873,000 | 18,712,000 | 10,962,000 | 8,542,000 | 10,211,000 | 10,305,000 | — |
| Total liabilities | 45,395,000 | 37,179,000 | 25,791,000 | 19,962,000 | 14,860,000 | 14,670,000 | 20,063,000 | 13,125,000 |
| Shareholders' deficit: | ||||||||
| Common shares, no par value, unlimited authorized shares, 2,552,429 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 459,771,000 | 459,771,000 | 459,771,000 | 459,771,000 | 459,771,000 | 457,404,000 | 452,302,000 | 452,294,000 |
| Additional paid-in capital | 83,942,000 | 83,813,000 | 83,771,000 | 83,727,000 | 83,662,000 | 83,336,000 | 82,262,000 | 82,275,000 |
| Accumulated other comprehensive loss | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) |
| Accumulated deficit | (574,069,000) | (566,435,000) | (558,676,000) | (553,553,000) | (546,510,000) | (540,967,000) | (539,382,000) | (532,429,000) |
| Total shareholders' deficit | (34,672,000) | (27,167,000) | (19,450,000) | (14,371,000) | (7,393,000) | (4,543,000) | (9,134,000) | (2,176,000) |
| Total liabilities and shareholders' deficit | 10,723,000 | 10,012,000 | 6,341,000 | 5,591,000 | 7,467,000 | 10,127,000 | 10,929,000 | 10,949,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.